Effect of enzyme extracts isolated from white-rot fungi on chemical composition and in vitro digestibility of wheat straw

A series of in vitro experiments were completed to evaluate the potential of enzyme extracts, obtained from the white-rot fungi Trametes versicolor (TV1, TV2), Bjerkandera adusta (BA) and Fomes fomentarius (FF), to increase degradation of cell wall components of wheat straw. The studies were conducted as a completely randomized design and analysed using one-way ANOVA. Enzyme activities of the extracts, previously obtained from a liquid culture medium, were characterized in terms of laccase and peroxidase for ligninolytic activity. Carboxymethyl cellulase (CMCase) and avicell digesting cellulase (Avicelase) were used for cellulolytic enzyme assays. Wheat straw samples were incubated with enzyme extracts in a citrate buffer (pH 5.0) in a forced air oven at 25 °C for 6 days. In vitro NDF digestibility (IVNDFD), and the rate and extent of NDF fermentation, without and after incubation with the white-rot enzyme extracts, were determined using a gravimetric microbiological method and a gas production technique, respectively. Results from cell wall chemical composition showed that TV2 and BA enzyme extracts decreased NDF concentration (

The potential of white-rot fungi to degrade phorbol esters of Jatropha curcas L. seed cake

The potential of solid-state cultivation, with three white-rot fungi (Bjerkandera adusta, Ganoderma resinaceum and Phlebia rufa), to decrease phorbol esters concentration of Jatropha curcas L. was evaluated in this study. Incubation was conducted in 250¿mL Erlenmeyer flasks without agitation at 28°C for 30 days. Phorbol esters were analyzed by reverse-phase HPLC after an extraction procedure using dichloromethane. All fungi studied were able to decrease the concentration of phorbol esters, mainly B. adusta and P. rufa which significantly reduced (

Modification of wheat straw lignin by solid state fermentation with white-rot fungi

The potential of crude enzyme extracts, obtained from solid state cultivation of four white-rot fungi (Trametes versicolor, Bjerkandera adusta, Ganoderma applanatum and Phlebia rufa), was exploited to modify wheat straw cell wall. At different fermentation times, manganese-dependent peroxidase (MnP), lignin peroxidase (LiP), laccase, carboxymethylcellulase (CMCase), avicelase, xylanase and feruloyl esterase activities were screened and the content of lignin as well as hydroxycinnamic acids in fermented straw were determined. All fungi secreted feruloyl esterase while LiP was only detected in crude extracts from B. adusta. Since no significant differences (P > 0.05) were observed in remaining lignin content of fermented straw, LiP activity was not a limiting factor of enzymatic lignin removal process. The levels of esterified hydroxycinnamic acids degradation were considerably higher than previous reports with lignocellulosic biomass. The data show that P. rufa, may be considered for more specific studies as higher ferulic and p-coumaric acids degradation was observed for earlier incubation time

Brazilian Guidelines For The Diagnosis Of Narcolepsy [diretrizes Brasileiras Para O Diagnóstico Da Narcolepsia]

This manuscript contains the conclusion of the consensus meeting on the diagnosis of narcolepsy based on the review of Medline publications between 1980-2010. Narcolepsy is a chronic disorder with age at onset between the first and second decade of life. Essential narcolepsy symptoms are cataplexy and excessive sleepiness. Cataplexy is defined as sudden, recurrent and reversible attacks of muscle weakness triggered by emotions. Accessory narcolepsy symptoms are hypnagogic hallucinations, sleep paralysis and nocturnal fragmented sleep. The clinical diagnosis according to the International Classification of Sleep Disorders is the presence of excessive sleepiness and cataplexy. A full in-lab polysomnography followed by a multiple sleep latency test is recommended for the confirmation of the diagnosis and co-morbidities. The presence of two sleep-onset REM period naps in the multiple sleep latency test is diagnostic for cataplexy-free narcolepsy. A positive HLA-DQB1*0602 with lower than 110pg/mL level of hypocretin-1 in the cerebrospinal fluid is required for the final diagnosis of cataplexy- and sleep-onset REM period-free narcolepsy.323294304(2005) International Classification of Sleep Disorders, Second Edition: Diagnostic and Coding Manual, , American Academy of Sleep Medicine. Westchester, IL: American Academy of Sleep MedicineLongstreth Jr., W.T., Ton, T.G., Koepsell, T., Gersuk, V.H., Hendrickson, A., Velde, S., Prevalence of narcolepsy in King County, Washington, USA (2009) Sleep Med, 10 (4), pp. 422-426Longstreth Jr., W.T., Koepsell, T.D., Ton, T.G., Hendrickson, A.F., Van Belle, G., The epidemiology of narcolepsy (2007) Sleep, 30 (1), pp. 13-26Silber, M.H., Krahn, L.E., Olson, E.J., Pankratz, V.S., The epidemiology of narcolepsy in Olmsted County, Minnesota: A population-based study (2002) Sleep, 25 (2), pp. 197-202Hublin, C., Kaprio, J., Partinen, M., Koskenvuo, M., Heikkila, K., Koskimies, S., Guillemmault, C., The prevalence of narcolepsy: An epidemiological study of the Finnish twin cohort (1994) Annals of Neurology, 35 (6), pp. 709-716. , DOI 10.1002/ana.410350612Wing, Y.K., Li, R.H., Lam, C.W., Ho, C.K., Fong, S.Y., Leung, T., The prevalence of narcolepsy among Chinese in Hong Kong (2002) Ann Neurol, 51 (5), pp. 578-584Mignot, E., Genetic and familial aspects of narcolepsy (1998) Neurology, 50 (2 SUPPL. 1), pp. S16-22Mignot, E., Lin, L., Rogers, W., Honda, Y., Qiu, X., Lin, X., Okun, M., Risch, N., Complex HLA-DR and -DQ interactions confer risk of narcolepsycataplexy in three ethnic groups (2001) Am J Hum Genet, 68 (3), pp. 686-699Pelin, Z., Guilleminault, C., Risch, N., Grumet, F.C., Mignot, E., HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups (1998) Tissue Antigens, 51 (1), pp. 96-100. , US Modafinil in Narcolepsy Multicenter Study GroupMignot, E., Kimura, A., Latlermann, A., Lin, X., Yasunaga, S., Mueller-Eckhardt, G., Rattazzi, C., Underbill, P., Extensive HLA class II studies in 58 non-DRB 1*15 (DR2) narcoleptic patients with cataplexy (1997) Tissue Antigens, 49 (4), pp. 329-341Ellis, M.C., Hetisimer, A.H., Ruddy, D.A., Hansen, S.L., Kronmal, G.S., McClelland, E., Quintana, L., Mignot, E., HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy (1997) Immunogenetics, 46 (5), pp. 410-417Mignot, E., Lin, X., Arrigoni, J., Macaubas, C., Olive, F., Hallmayer, J., Underhill, P., Grumet, F.C., DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans (1994) Sleep, 17 (8 SUPPL.), pp. S60-7Mignot, E., Hayduk, R., Black, J., Grumet, F.C., Guilleminault, C., HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients (1997) Sleep, 20 (11), pp. 1012-1020Morgun, A., Gonçalves-Primo, A., Shulzhenko, N., Rampim, G.F., Mine, K.L., Gerbase-DeLima, M., HLA-DQB1 and -DRB1 Alleles, Cytokine Polymorphismis and KIR Gene Frequencies in a Population (Caucasian) from South East Brazil (2004) Hum Immunol, 65 (9), pp. 879-882Temin, J., Marques, G.D., Morgun, A., Shulzhenko, N., Rampim, G.F., Gerbase-de Lima, M., HLA-DQB1 and -DRB1 Alleles and Cytokine Polymorphismis in a Mulatto population from South East Brazil (2004) Hum Immunol, 65 (9), pp. 882-886Miyagawa, T., Honda, M., Kawashima, M., Shimada, M., Tanaka, S., Honda, Y., Tokunaga, K., Polymorphism located in TCRA locus confers susceptibility to essential hypersomnia with HLA-DRB1*1501-DQB1*0602 haplotype (2010) J Hum Genet, 55 (1), pp. 63-65Hallmayer, J., Faraco, J., Lin, L., Hesselson, S., Winkelmann, J., Kawashima, M., Mayer, G., Mignot, E., Narcolepsy is strongly associated with the T-cell receptor alpha locus (2009) Nat Genet, 41 (6), pp. 708-711Dauvilliers, Y., Neidhart, E., Lecendreux, M., Billiard, M., Tafti, M., MAO-A and COMT polymorphisms and gene effects in narcolepsy (2001) Molecular Psychiatry, 6 (4), pp. 367-372. , DOI 10.1038/sj.mp.4000911Dauvilliers, Y., Neidhart, E., Billiard, M., Tafti, M., Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil (2002) Pharmacogenomics Journal, 2 (1), pp. 65-68. , DOI 10.1038/sj.tpj.6500088Dauvilliers, Y., Arnulf, I., Narcolepsie avec cataplexie (2008) Revue Neurologique, 164 (8-9), pp. 634-645Dauvilliers, Y., Arnulf, I., Mignot, E., Narcolepy with cataplexy (2007) Lancet, 369 (9560), pp. 499-511Nishino, S., Clinical and neurobiological aspects of narcolepsy (2007) Sleep Med, 8 (4), pp. 373-399Nishino, S., Narcolepsy (2006) Sleep Med Clin, 1, pp. 47-61Dauvilliers, Y., Billiard, M., Montplaisir, J., Clinical aspects and pathophysiology of narcolepsy (2003) Clin Neurophysiol, 114 (11), pp. 2000-2017Thannickal, T.C., Nienhuis, R., Siegel, J.M., Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy (2009) Sleep, 32 (8), pp. 993-998Overeem, S., Black III, J.L., Lammers, G.J., Narcolepsy: Immunological aspects (2008) Sleep Med Rev, 12 (2), pp. 95-107Boehmer, L.N., Wu, M.-F., John, J., Siegel, J.M., Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity (2004) Experimental Neurology, 188 (2), pp. 292-299. , DOI 10.1016/j.expneurol.2004.04.006, PII S0014488604001396Vignatelli, L., D'Alessandro, R., Mosconi, P., Ferini-Strambi, L., Guidolin, L., De Vincentiis, A., Plazzi, G., Health-related quality of life in Italian patients with narcolepsy: The SF-36 health survey (2004) Sleep Med, 5 (5), pp. 467-475. , GINSEN (Gruppo Italiano Narcolessia-Studio Epidemiologico Nazionale)Rieger, M., Mayer, G., Gauggel, S., Attention deficits in patients with narcolepsy (2003) Sleep, 26 (1), pp. 36-43Bayon, V., Damien Léger, D., Philip, P., Socio-professional handicap and accidental risk in patients with hypersomnias of central origin (2009) Sleep Med, 13 (6), pp. 421-426Aldrich, M.S., Automobile accidents in patient with sleep disorders (1989) Sleep, 12 (6), pp. 487-494Fortuyn, H.A., Lappenschaar, M.A., Furer, J.W., Hodiamont, P.P., Rijnders, C.A., Renier, W.O., Buitelaar, J.K., Overeem, S., Anxiety and mood disorders in narcolepsy: A case-control study (2010) Gen Hosp Psychiatry, 32 (1), pp. 49-56Bonakis, A., Howard, R.S., Williams, A., Bonakis, A., Howard, R.S., Williams, A., Narcolepsy presenting as REM sleep behaviour disorder (2008) Clinical Neurol Neurosurg, 110 (5), pp. 518-520Dauvilliers, Y., Rompre, S., Gagnon, J.-F., Vendette, M., Petit, D., Montplaisir, J., REM sleep characteristics in narcolepsy and REM sleep behavior disorder (2007) Sleep, 30 (7), pp. 844-849Mattarozzi, K., Bellucci, C., Campi, C., Cipolli, C., Ferri, R., Franceschini, C., Mazzetti, M., Plazzi, G., Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy (2008) Sleep Med, 9 (4), pp. 425-433Nevsimalova, S., Prihodova, I., Kemlink, D., Linm, L., Mignot, E., REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy (2007) Sleep Med, 8 (7-8), pp. 784-786Nightingale, S., Orgill, J.C., Ebrahim, I.O., De Lacy, S.F., Agrawal, S., Williams, A.J., The association between narcolepsy and REM behavior disorder (RBD) (2005) Sleep Med, 6 (3), pp. 253-258Fortuyn, H.A., Swinkels, S., Buitelaar, J., Renier, W.O., Furer, J.W., Rijnders, C.A., Hodiamont, P.P., Overeem, S., High prevalence of eating disorders in narcolepsy with cataplexy: A case-control study (2008) Sleep, 31 (3), pp. 335-341Dahmen, N., Bierbrauer, J., Kasten, M., Increased prevalence of obesity in narcoleptic patients and relatives (2001) Eur Arch Psychiatry Clin Neurosci, 251 (2), pp. 85-89Chabas, D., Foulon, C., Gonzalez, J., Nasr, M., Lyon-Caen, O., Willer, J.C., Derenne, J.P., Arnulf, I., Eating disorder and metabolism in narcoleptic patients (2007) Sleep, 30 (10), pp. 1267-1273Kotagal, S., Krahn, L.E., Slocumb, N., A putative link between childhood narcolepsy and obesity (2004) Sleep Med, 5 (2), pp. 147-150Sansa, G., Iranzo, A., Santamaria, J., Obstructive sleep apnea in narcolepsy (2010) J Sleep Med, 11 (1), pp. 93-95Dahmen, N., Kasten, M., Wieczorek, S., Gencik, M., Epplen, J.T., Ullrich B, B., Increased frequency of migraine in narcoleptic patients: A confirmatory study (2003) Cephalalgia, 23 (1), pp. 14-19Dahmen, N., Querings, K., Grun, B., Bierbrauer, J., Increased frequency of migraine in narcoleptic patients (1999) Neurology, 52 (6), pp. 1291-1293Nishino, S., Kanbayashi, T., Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system (2005) Sleep Med Rev, 9 (4), pp. 269-310Billiard, M., Diagnosis of narcolepsy and idiopathic hypersomnia. An update based on the International Classification of Sleep Disorders (2007) Sleep Med Rev, 11 (5), pp. 377-388Sasai, T., Inoue, Y., Komada, Y., Sugiura, T., Matsushima, E., Comparison of clinical characteristics among narcolepsy with and without cataplexy and idiopathic hypersomnia without long sleep time, focusing on HLA-DRB1*1501/DQB1*0602 finding (2009) Sleep Med, 10 (9), pp. 961-966Arnulf, I., Zeitzer, J.M., File, J., Farber, N., Mignot, E., Kleine-Levin syndrome: A systematic review of 186 cases in the literature (2005) Brain, 128 (PART 12), pp. 2763-2776Doose, H., Myoclonic-astatic epilepsy in early childhood (1992) Epileptic Syndromes in Infancy, Childhood and Adolescence, pp. 103-114. , Roger J, Bureau M, Dravet C, editors. 2 ed. London: John LibbeyZeman, A., Douglas, N., Aylward, R., Narcolepsy mistaken for epilepsy (2001) BMJ, 322 (7280), pp. 216-218Zeman, A., Britton, T., Neil Douglas, D., Hansen, A., Hicks, J., Robin, H., Narcolepsy and excessive daytime sleepiness (2004) BMJ, 329 (7468), pp. 724-728Baumann, C.R., Bassetti, C.L., Valko, P.O., Haybaeck, J., Morten Keller, M., Clark, E., Stocker, R., Scammell, T.E., Loss of hypocretin (Orexin) neurons with traumatic brain injury (2009) Ann Neurol, 66 (4), pp. 555-559Droogleever-Fortuyn, H.A., Psychotic symptoms in narcolepsy: Phenomenology and a comparison with schizophrenia (2009) Gen Hospital Psychiatr, 31, pp. 146-154Ohayon, M.M., Priest, R.G., Caulet, M., Guilleminault, C., Hypnagogic and hypnopompic hallucinations: Pathologic phenomenon? (1996) Br J Psychiatry, 169 (4), pp. 459-467Ohayon, M.M., Zulley, J., Guilleminault, C., Smirne, S., Prevalence and pathologic association of sleep paralysis in the general population (1999) Neurology, 52 (6), pp. 1194-1200D'Cruz, O., Vaughn, B., Gold, S., Symptomatic cataplexy in pontomedullary lesions (1994) Neurology, 44 (11), pp. 2189-2191Iber, C., Ancoli-Israel, S., Chesson, A.L., Quan, S.F., (2007) The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications, , Westchester, Illinois: American Academy of Sleep MedicineKushida, C.A., Littner, M.R., Morgenthaler, T., Alessi, C.A., Bailey, D., Coleman Jr., J., Friedman, L., Wise, M., The indications for polysomnography and related proce dures (2005) Sleep, 28 (4), pp. 499-521Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test (2005) Sleep, 28, pp. 113-121. , Standards of Practice Committee of the American Academy of Sleep MedicineBroughton, R., Dunham, W., Newman, J., Lutley, K., Duschesne, P., Rivers, M., Ambulatory 24 hour sleep-wake monitoring in narcolepsy -cataplexy compared with matched control subjects (1988) Electroencephalogr Clin Neurophysiol, 70 (6), pp. 473-481Montplaisir, J., Billiard, M., Takahashi, S., Bell, I.R., Guilleminault, C., Dement, W.C., Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption (1978) Biol Psychiatry, 13 (1), pp. 73-89Montplaisir, J., Godbout, R., Nocturnal sleep of narcoleptic patients: Revisited (1986) Sleep, 9 (1 PART 2), pp. 159-161Vankova, J., Nevsimalova, S., Sonka, K., Spackova, N., Svejdova-Blazejova, K., Increased REM density in narcolepsy-cataplexy and the polysymptomatic form of idiopathic hypersomnia (2001) Sleep, 24 (6), pp. 707-711Dauvilliers, Y., Pennestri, M.H., Petit, D., Dhang-Vu, T., Lavigne, G., Montplaisir, J., Periodic leg movements during sleep and wakefulness in Narcolepsy J (2007) Sleep Res, 16 (3), pp. 333-339Arand, D., Bonnet, M., Hurwitz, T., Mitler, M., Rosa, R., Sangel, B., The Clinical Use of the MSLT and MWT (2005) Sleep, 28 (1), pp. 123-144Bonnet, M.H., ACNS clinical controversy: MSLT and MWT have limited clinical utility (2006) J Clin Neurophysiol, 23 (1), pp. 50-58Wise, M.S., Objective Measures of Sleepiness and Wakefulness: Application to the Real World? (2006) J Clin Neurophysiol, 23 (1), pp. 39-49Mitler, M.M., Gujavarty, K.S., Browman, C.P., Maintenance of wake fulness test: A polysomnographic technique for evaluation treat ment efficacy in patients with excessive somnolence (1982) Electroen Cephalogr Clin Neurophysiol, 53 (6), pp. 658-661Doghramji, K., Mitler, M., Sangal, B., Shapiro, Taylor, S., Shapiro, C., Taylor, S., Youakim, J.M., A normative study of the maintenance of wakefulness test (MWT) (1997) Electroencephalogr Clin Neurophysiol, 103 (5), pp. 554-562Johns, M.W., A new method for measuring daytime sleepiness: The Epworth sleepiness scale (1991) Sleep, 14 (6), pp. 540-545Johns, M.W., Sleepiness in different situations measured by the Epworth sleepiness scale (1994) Sleep, 17 (8), pp. 703-710Johns, M.W., Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the Epworth sleepiness scale: Failure of the MSLT as a gold standard (2000) J Sleep Res, 9 (1), pp. 5-11Lin, L., Hungs, M., Mignot, E., Narcolepsy and the HLA region (2001) J Neuroimmunol, 117 (1-2), pp. 9-20Bougin, P., Zeitzer, J.M., Mignot, E., CSF hypocretin-1 assessment in sleep and neurological disorders (2008) Lancet Neurol, 7 (7), pp. 649-662De Lecea, L., Kilduff, T.S., Peyron, C., Gao, X., Foye, P.E., Danielson, P.E., Fukuhara, C., Sutcliffe, J.G., The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity (1998) Proc Natl Acad Sci USA, 95 (1), pp. 322-327Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Williams, S.C., Yanagisawa, M., Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior (1998) Cell, 92 (4), pp. 573-585Fronczek, R., Bauman, C.R., Lammers, G.J., Bassetti, C.L., Overeem, S., Hypocretin/orexin disturbances in neurological disorders (2009) Sleep Med Rev, 13 (1), pp. 9-22Shchenko, D., Murillo-Rodriguez, E., Lin, L., Xu, M., Hallett, L., Nishino, S., Lin, L., Shiromani, P.J., Relationship between CSF hypocretin levels and hypocretin neuronal loss (2003) Exp Neurol, 184 (2), pp. 1010-1016Mignot, E., Lammers, G.J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., Overeem, S., Nishino, S., The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias (2002) Arch Neurol, 59 (10), pp. 1553-1562Dauvilliers, Y., Baumann, C.R., Carlander, B., Bischof, M., Blatter, T., Lecendreux, M., Maly, F., Bassetti, C.L., CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions (2003) J Neurol Neurosurg Psychiatry, 74 (12), pp. 1667-1673Baumann, C.R., Bassetti, C.L., Hypocretins (orexins) and sleep-wake disorders (2005) Lancet Neurol, 4 (10), pp. 673-68

Brazilian Guidelines For The Treatment Of Narcolepsy [diretrizes Brasileiras Para O Tratamento Da Narcolepsia]

This manuscript contains the conclusion of the consensus meeting of the Brazilian Sleep Association with Brazilian sleep specialists on the treatment of narcolepsy based on the review of medical literature from 1980 to 2010. The manuscript objectives were to reinforce the use of agents evaluated in randomized placebo-controlled trials and to issue consensus opinions on the use of other available medications as well as to inform about safety and adverse effects of these medications. Management of narcolepsy relies on several classes of drugs, namely, stimulants for excessive sleepiness, antidepressants for cataplexy and hypnotics for disturbed nocturnal sleep. Behavioral measures are likewise valuable and universally recommended. All therapeutic trials were analyzed according to their class of evidence. Recommendations concerning the treatment of each single symptom of narcolepsy as well as general recommendations were made. Modafinil is the first-line pharmacological treatment of excessive sleepiness. Second-line choices for the treatment of excessive sleepiness are slow-release metylphenidate followed by mazindol. The first-line treatments of cataplexy are the antidepressants, reboxetine, clomipramine, venlafaxine, desvenlafaxine or high doses of selective serotonin reuptake inibitors antidepressants. As for disturbed nocturnal sleep the best option is still hypnotics. Antidepressants and hypnotics are used to treat hypnagogic hallucinations and sleep paralysis.323305314Morgenthaler, T.I., Kapur, V.K., Brown, T., Swick, T.J., Alessi, C., Aurora, R.N., Boehlecke, B., Zak, R., Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin (2007) Sleep, 30 (12), pp. 1705-1711. , Standards of Practice Committee of the American Academy of Sleep MedicineSackett, D.L., Rules of evidence and clinical recommendations for the management of patients (1993) Can J Cardiol, 9 (6), pp. 487-489Eddy, D., (1992) A Manual for Assessing Health Practices and Designing Practice Policies: The Explicit Approach, , Philadelphia: American College of PhysiciansLevels of Evidence, , http://www.cebm.net/index.aspx0=1025, Web Site. [cited 2009 dez 16]. Available fromDelbecq, A., Vande Ven, A., A group process model for prob lem identification and programme planning (1971) J Appl Behav Sci, 7, pp. 467-492Britton, T., Hansen, A., Hicks, J., Howard, R., Meredith, A., (2002) Guidelines on the Diagnosis and Management of Narcolepsy in Adults and Children. Evidence-Based Guidelines for the UK with Graded Recommendations, , Ashtead, UK: Taylor Patten Communications LtdGuilleminault, C., Fromherz, S., Narcolepsy: Diagnosis and management (2005) Principles and Practice of Sleep Medicine, , Kryger MH, Roth T, Dement WC, editors. 4th ed. Philadelphia: Saunders, ElsevierBilliard, M., Bassetti, C., Dauvilliers, Y., Dolenc-Groselj, L., Lammers, G.J., Mayer, G., Pollmacher, T., Sonka, K., EFNS guidelines on management of narcolepsy (2006) Eur J Neurol, 13 (10), pp. 1035-1048Wise, M.S., Arand, D.L., Auger, R.R., Brooks, S.N., Watson, N.F., Treatment of narcolepsy and other hypersomnias of central origin (2007) Sleep, 30 (12), pp. 1712-1727Roehrs, T., Zorick, F., Wittig, R., Paxton, C., Sicklesteel, J., Roth, T., Alerting effects of naps in patients with narcolepsy (1986) Sleep, 9, pp. 194-199Mullington, J., Broughton, R., Scheduled naps in the management of daytime sleepiness in narcolepsy- Cataplexy (1993) Sleep, 16 (5), pp. 444-456Rogers, A.E., Aldrich, M.S., Lin, X., A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy (2001) Sleep, 24 (4), pp. 385-391Chen, W., Mignot, E., Narcolepsy and hypersomnia of central origin: Diagnosis, differential pearls, and management (2007) Review of Sleep Medicine, pp. 75-94. , Barkoukis T, Avidan A, editors. 2nd ed. Philadelphia: Butterworth Heinman, ElsevierZaharna, M., Dimitriu, A., Guilleminault, C., Expert opinion on pharmacotherapy of narcolepsy (2010) Expert Opin Pharmacother, , In pressZolkowska, D., Jain, R., Rothman, R.B., Partilla, J.S., Roth, B.L., Setola, V., Prisinzano, T.E., Baumann, M.H., Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil (2009) J Pharmacol Exp Ther, 329 (2), pp. 738-746Boutrel, B., Koob, G.F., What keeps us awake: The neuropharmacology of stimulants and wakefulness-promoting medications (2004) Sleep, 27 (6), pp. 1181-1194Volkow, N.D., Fowler, J.S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Hooker, J.M., Apelskog-Torres, K., Effects of modafinil on dopamine and dopamine transporters in the male human brain (2009) JAMA, 301 (11), pp. 1148-1154Qu, W.M., Huang, Z.L., Xu, X.H., Matsumoto, N., Urade, Y., Dopamin ergic D1 and D2 receptors are essential for the arousal effect of modafinil (2008) J Neurosci, 28 (34), pp. 8462-8469Beierlein, M., Gibson, J.R., Connors, B.W., A network of electrically coupled interneurons drives synchronized inhibition in neocortex (2000) Nat Neurosci, 3 (9), pp. 904-910Hestrin, S., Galarreta, M., Electrical synapses define networks of neocortical GABAergic neurons (2005) Trends in Neurosciences, 28 (6 SPEC. ISS), pp. 304-309. , DOI 10.1016/j.tins.2005.04.001, PII S0166223605000998Garcia-Rill, E., Heister, D.S., Ye, M., Charlesworth, A., Hayar, A., Electrical coupling: Novel mechanism for sleep-wake control (2007) Sleep, 30 (11), pp. 1405-1414Urbano, F.J., Leznik, E., Llinas, R.R., Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling (2007) Proceedings of the National Academy of Sciences of the United States of America, 104 (30), pp. 12554-12559. , DOI 10.1073/pnas.0705087104Beck, P., Odle, A., Wallace-Hunt, T., Skinner, R.D., Garcia-Rill, E., Modafinil increases arousal determined by P13 potential am plitude: An effect blocked by gap junction antagonists (2008) Sleep, 31 (12), pp. 1647-1654Ferraro, L., Tanganelli, S., O'Connor, W.T., Antonelli, T., Rambert, F., Fuxe, K., The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: Possible involvement of the serotonergic 5-HT3 receptor (1996) Neuroscience Letters, 220 (1), pp. 5-8. , DOI 10.1016/S0304-3940(96)13212-2, PII S0304394096132122Ferraro, L., Antonelli, T., O'Connor, W.T., Tanganelli, S., Rambert, F., Fuxe, K., The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus (1997) NeuroReport, 8 (13), pp. 2883-2887De La Mora, M.P., Aguilar-Garcia, A., Ramon-Frias, T., Ramirez-Ramirez, R., Mendez-Franco, J., Rambert, F., Fuxe, K., Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus (1999) Neuroscience Letters, 259 (3), pp. 181-185. , DOI 10.1016/S0304-3940(98)00905-7, PII S0304394098009057Willie, J.T., Renthal, W., Chemelli, R.M., Miller, M.S., Scammell, T.E., Yanagisawa, M., Sinton, C.M., Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates (2005) Neuroscience, 130 (4), pp. 983-995. , DOI 10.1016/j.neuroscience.2004.10.005, PII S0306452204009339Scammell, T.E., Estabrooke, I.V., McCarthy, M.T., Chemelli, R.M., Yanagisawa, M., Miller, M.S., Saper, C.B., Hypothalamic arousal regions are activated during modafinil-induced wakefulness (2000) J Neurosci, 20 (22), pp. 8620-8628Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy (1998) Ann Neurol, 43 (1), pp. 88-97. , US Modafinil in Narcolepsy Multicenter Study GroupRandomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy (2000) Neurology, 54 (5), pp. 1166-1175. , US Modafinil in Narcolepsy Multicenter Study GroupBroughton, R.J., Fleming, J.A.E., George, C.F.P., Hill, J.D., Kryger, M.H., Moldofsky, H., Montplaisir, J.Y., Murphy, W.F., Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy (1997) Neurology, 49 (2), pp. 444-451Mitler, M.M., Hirsh, J., Hirshkowitz, M., Guilleminault, C., Long-term efficacy and safety of modafinil (PROVIGIL) for the treatment of excessive daytime sleepiness associated with narcolepsy (2000) Sleep Med, 1 (3), pp. 231-243. , for the US Modafinil in Narcolepsy Multicenter Study GroupMoldofsky, H., Broughton, R.J., Hill, J.D., A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy (2000) Sleep Med, 1 (2), pp. 109-116Schwartz, J., Feldman, N.T., Bogan, R.K., Dose response and dose regimen effects of modafinil in sustaining daytime wakefulness in narcoleptic patients with residual excessive sleepiness (2005) J Neuropsychiatry Clin Neurosci, 17 (3), pp. 405-412Dauvilliers, Y., Neidhart, E., Billiard, M., Tafti, M., Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil (2002) Pharmacogenomics Journal, 2 (1), pp. 65-68. , DOI 10.1038/sj.tpj.6500088Robertson Jr., P., Hellriegel, E.T., Clinical pharmacokinetic profile of modafinil (2003) Clin Pharmacokinet, 42 (2), pp. 123-137Wong, Y.N., Simcoe, D., Hartman, L.N., Laughton, W.B., King, S.P., McCormick, G.C., Grebow, P.E., A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers (1999) Journal of Clinical Pharmacology, 39 (1), pp. 30-40. , DOI 10.1177/00912709922007534Schawartz, J.R., Modafinil in the treatment of excessive sleepiness (2009) Drug des Devel Ther, 2, pp. 71-85Kumar, R., Approved and investigational uses of modafinil: An evidence-based review (2008) Drugs, 68 (13), pp. 1803-1839Walsleben, J.A., Ristanovic, R., Hirshkowitz, M., Provigil (modafinil) in the treatment of excessive daytime sleepiness in narcolepsy: Effect of previous treatment with stimulants on clinical response and safety (2000) Sleep, 23, pp. A303-4Schwartz, J.R.L., Feldman, N.T., Fry, J.M., Harsh, J., Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants (2003) Sleep Medicine, 4 (1), pp. 43-49. , DOI 10.1016/s1389-9457(02)00240-xThorpy, M.J., Schwartz, J.R.L., Kovacevic-Ristanovic, R., Hayduk, R., Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: An open-label safety study assessing three strategies (2003) Psychopharmacology, 167 (4), pp. 380-385Roth, T., Schwartz, J.R.L., Hirshkowitz, M., Erman, M.K., Dayno, J.M., Arora, S., Evaluation of the safety of modafinil for treatment of excessive sleepiness (2007) Journal of Clinical Sleep Medicine, 3 (6), pp. 595-602Jasinski, D.R., Kovacevi-Ristanovi, R., Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy (2000) Clin Neuropharmacol, 23 (3), pp. 149-156Myrick, H., Malcolm, R., Taylor, B., LaRowe, S., Modafinil: Preclinical, clinical, and post-marketing surveillance - A review of abuse liability issues (2004) Ann Clin Psychiatry, 16 (2), pp. 101-106Jasisnki, D.R., An evaluation of the abuse potential of modafinil using methylphenidate as a reference (2000) J Psychopharmacol, 14 (1), pp. 53-60Andersen, M.L., Kessler, E., Murnane, K.S., McClung, J.C., Tufik, S., Howell, L.L., Dopamine transporter-related effects of modafinil in rhesus monkeys (2010) Pshychopharmacology, 210 (3), pp. 439-448. , BerlProvigil Consumer Information, , www.fda.gov/cder/consumerinfo/druginfo/provigil, [cited 2009 mar 2]. Available fromBogan, R.K., Armodafinil in the treatment of excessive sleepiness (2010) Expert Opin Pharmacother, 11 (6), pp. 993-1002Nishino, S., Okuro, M., Emerging treatments for narcolepsy and its related disorders (2010) Expert Opin Emerg Drugs, 15 (1), pp. 139-158Auger, R.R., Goodman, S.H., Silber, M.H., Krahn, L.E., Pankratz, V.S., Slocumb, N.L., Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study (2005) Sleep, 28 (6), pp. 667-672Dauvilliers, Y., Arnulf, I., Mignot, E., Narcolepsy with cataplexy (2007) Lancet, 369 (9560), pp. 499-511Mitler, M.M., Hajdukovik, R., Relative efficacy of drugs used for the treatment of narcolepsy (1991) Sleep, 14 (3), pp. 218-220Wallin, M.T., Mahowald, M.W., Blood pressure effects of long-term stimulant use in disorders of hypersomnolence (1998) J Sleep Res, 7 (3), pp. 209-215Thorpy, M., Current concepts in the etiology, diagnosis and treatment of narcolepsy (2001) Sleep Med, 2 (1), pp. 5-17Mitler, M.M., Aldrich, M.S., Koob, G.F., Zarcone, V.P., Narcolepsy and its treatment with stimulants. ASDA standards of practice (1994) Sleep, 17 (4), pp. 352-371Shindler, J., Schachter, M., Brincat, S., Parkes, J.D., Amphetamine, mazindol, and fencamfamin in narcolepsy (1985) Br Med J (Clin Res Ed), 290 (6476), pp. 1167-1170Lijima, S., Sugita, Y., Teshima, Y., Hishikawa, Y., Therapeutic effects of mazindol on narcolepsy (1986) Sleep, 9 (1 PART 2), pp. 265-268Alvarez, B., Dahlitz, M., Grimshaw, J., Parkes, J.D., Mazindol in long-term treatment of narcolepsy (1991) Lancet, 337 (8752), pp. 1293-1294Mayer, G., Meier-Ewert, K., Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study (1995) Clin Neuropharmacol, 18 (4), pp. 306-319Hublin, C., Partinen, M., Heinonen, E., Puuka, P., Salmi, T., Selegiline in the treatment of narcolepsy (1994) Neurology, 44 (11), pp. 2095-2101Pratt, D.S., Dubois, R.S., Hepatotoxicity due to pemoline (Cylert): A report of two cases (1990) J Pediatr Gastroent Nutri, 10 (2), pp. 239-241Nehra, A., Mullick, F., Ishak, K.G., Zimmerman, H.J., Pemoline-associated hepatic injury (1990) Gastroenterol, 99 (5), pp. 1517-1519Beaumont, M., Batejat, D., Pierard, C., Coste, O., Doireau, P., Van Beers, P., Chauffard, F., Lagarde, D., Slow release caffeine and prolonged (64-h) continuous wakefulness: Effects on vigilance and cognitive performance (2001) Journal of Sleep Research, 10 (4), pp. 265-276. , DOI 10.1046/j.1365-2869.2001.00266.xHoughton, W.C., Scammell, T.E., Thorpy, M., Pharmacotherapy for cataplexy (2004) Sleep Med Rev, 8 (5), pp. 355-366Vignatelli, L., D'Alessandro, R., Candelise, L., Antidepressant drugs for narcolepsy (2005) Cochrane Database Syst Rev, 20, p. 3. , CD0003724Frey, J., Darbonne, C., Fluoxetine suppresses human cataplexy: A pilot study (1994) Neurology, 44 (4), pp. 707-709Poceta, J.S., Hajdukovic, R., Mitler, M.M., Improvement in cataplexy with yohimbine and paroxetine: Case report (1994) Sleep Res, 23, p. 304Thirumalai, S.S., Shubin, R.A., The use of citalopram in resistant cataplexy (2000) Sleep Med, 1 (4), pp. 313-316Smith, M., Parkes, J.D., Dahlitz, M., Venlafaxine in the treatment of the narcoleptic syndrome (1996) J Sleep Res, 5, p. 217Larrosa, O., De La Llave, Y., Bario, S., Granizo, J.J., Garcia-Bor Reguero, D., Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: A pilot study (2001) Sleep, 24 (3), pp. 282-285Mayer, G., Meier-Ewert, K., Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study (1995) Clin Neuropharmacol, 18 (4), pp. 306-319A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy (2002) Sleep, 25 (1), pp. 42-49. , US XYREM Multicenter Study GroupFurther evidence support ing the use of sodium oxybate for the treatment of cataplexy: A double-blind, placebo-controlled study in 228 patients (2005) Sleep Med, 6 (5), pp. 415-421. , U.S. XYREM Multicenter Study GroupA double-blind placebo controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy (2005) J Clin Sleep Med, 1 (4), pp. 391-397. , XYREM International Study GroupBlack, J., Houghton, W.C., Sodium oxybate improves excessive daytime sleepiness in narcolepsy (2006) Sleep, 29 (7), pp. 939-946Lammers, G.J., Bassetti, C., Billiard, M., Black, J., Broughton, R., Dauvilliers, Y., Ferini Strambi, L., Thorpy, M., Sodium oxybate is an effective and safe treatment for narcolepsy (2010) Sleep Med, 11 (1), pp. 105-106Grozinger, M., Hartter, S., Hiemke, C., Griese, E.-U., Roschke, J., Interaction of modafinil and clomipramine as comedication in a narcoleptic patient (1998) Clinical Neuropharmacology, 21 (2), pp. 127-129Wu, D., Victoria Otton, S., Inaba, T., Kalow, W., Sellers, E.M., Interactions of amphetamine analogs with human liver CYP2D6 (1997) Biochemical Pharmacology, 53 (11), pp. 1605-1612. , DOI 10.1016/S0006-2952(97)00014-2, PII S0006295297000142Thorpy, M.J., Snyder, M., Aloe, F.S., Ledereich, P.S., Starz, K.E., Short-term triazolam use improves nocturnal sleep of narcoleptics (1992) Sleep, 15 (3), pp. 212-216Bonakis, A., Howard, R.S., Ebrahim, I.O., Merritt, S., Williams, A., REM sleep behaviour disorder (RBD) and its associations in young patients (2009) Sleep Med, 10 (6), pp. 641-645Suzanne Hoover-Stevens, S., Ruzica Kovacevic-Ristanovic, R., Management of narcolepsy in pregnancy (2000) CIin Neuropharmacol, 23 (4), pp. 175-181Rogers, A.E., Aldrich, M.S., Berrios, A.M., Rosenberg, R.S., Compliance with stimulant medications in patients with narcolepsy (1997) Sleep, 20 (1), pp. 28-3

Determination of inhibition in the enzymatic hydrolysis of cellobiose using hybrid neural modeling

Neural networks and hybrid models were used to study substrate and product inhibition observed in the enzymatic hydrolysis of cellobiose at 40ºC, 50ºC and 55ºC, pH 4.8, using cellobiose solutions with or without the addition of exogenous glucose. Firstly, the initial velocity method and nonlinear fitting with Statistica<FONT FACE=Symbol>Ò</FONT> were used to determine the kinetic parameters for either the uncompetitive or the competitive substrate inhibition model at a negligible product concentration and cellobiose from 0.4 to 2.0 g/L. Secondly, for six different models of substrate and product inhibitions and data for low to high cellobiose conversions in a batch reactor, neural networks were used for fitting the product inhibition parameter to the mass balance equations derived for each model. The two models found to be best were: 1) noncompetitive inhibition by substrate and competitive by product and 2) uncompetitive inhibition by substrate and competitive by product; however, these models’ correlation coefficients were quite close. To distinguish between them, hybrid models consisting of neural networks and first principle equations were used to select the best inhibition model based on the smallest norm observed, and the model with noncompetitive inhibition by substrate and competitive inhibition by product was shown to be the best predictor of cellobiose hydrolysis reactor behavior

Fungal Planet description sheets: 716–784

Novel species of fungi described in this study include those from various countries as follows: Australia, Chaetopsina eucalypti on Eucalyptus leaf litter, Colletotrichum cobbittiense from Cordyline stricta × C. australis hybrid, Cyanodermella banksiae on Banksia ericifolia subsp. macrantha, Discosia macrozamiae on Macrozamia miquelii, Elsinoë banksiigena on Banksia marginata, Elsinoë elaeocarpi on Elaeocarpus sp., Elsinoë leucopogonis on Leucopogon sp., Helminthosporium livistonae on Livistona australis, Idriellomyces eucalypti (incl. Idriellomyces gen. nov.) on Eucalyptus obliqua, Lareunionomyces eucalypti on Eucalyptus sp., Myrotheciomyces corymbiae (incl. Myrotheciomyces gen. nov., Myrotheciomycetaceae fam. nov.), Neolauriomyces eucalypti (incl. Neolauriomyces gen. nov., Neolauriomycetaceae fam. nov.) on Eucalyptus sp., Nullicamyces eucalypti (incl. Nullicamyces gen. nov.) on Eucalyptus leaf litter, Oidiodendron eucalypti on Eucalyptus maidenii, Paracladophialophora cyperacearum (incl. Paracladophialophoraceae fam. nov.) and Periconia cyperacearum on leaves of Cyperaceae, Porodiplodia livistonae (incl. Porodiplodia gen. nov., Porodiplodiaceae fam. nov.) on Livistona australis, Sporidesmium melaleucae (incl. Sporidesmiales ord. nov.) on Melaleuca sp., Teratosphaeria sieberi on Eucalyptus sieberi, Thecaphora australiensis in capsules of a variant of Oxalis exilis. Brazil, Aspergillus serratalhadensis from soil, Diaporthe pseudoinconspicua from Poincianella pyramidalis, Fomitiporella pertenuis on dead wood, Geastrum magnosporum on soil, Marquesius aquaticus (incl. Marquesius gen. nov.) from submerged decaying twig and leaves of unidentified plant, Mastigosporella pigmentata from leaves of Qualea parviflorae, Mucor souzae from soil, Mycocalia aquaphila on decaying wood from tidal detritus, Preussia citrullina as endophyte from leaves of Citrullus lanatus, Queiroziella brasiliensis (incl. Queiroziella gen. nov.) as epiphytic yeast on leaves of Portea leptantha, Quixadomyces cearensis (incl. Quixadomyces gen. nov.) on decaying bark, Xylophallus clavatus on rotten wood. Canada, Didymella cari on Carum carvi and Coriandrum sativum. Chile, Araucasphaeria foliorum (incl. Araucasphaeria gen. nov.) on Araucaria araucana, Aspergillus tumidus from soil, Lomentospora valparaisensis from soil. Colombia, Corynespora pseudocassiicola on Byrsonima sp., Eucalyptostroma eucalyptorum on Eucalyptus pellita, Neometulocladosporiella eucalypti (incl. Neometulocladosporiella gen. nov.) on Eucalyptus grandis × urophylla, Tracylla eucalypti (incl. Tracyllaceae fam. nov., Tracyllalales ord. nov.) on Eucalyptus urophylla. Cyprus, Gyromitra anthracobia (incl. Gyromitra subg. Pseudoverpa) on burned soil. Czech Republic, Lecanicillium restrictum from the surface of the wooden barrel, Lecanicillium testudineum from scales of Trachemys scripta elegans. Ecuador, Entoloma yanacolor and Saproamanita quitensis on soil. France, Lentithecium carbonneanum from submerged decorticated Populus branch. Hungary, Pleuromyces hungaricus (incl. Pleuromyces gen. nov.) from a large Fagus sylvatica log. Iran, Zymoseptoria crescenta on Aegilops triuncialis. Malaysia, Ochroconis musicola on Musa sp. Mexico, Cladosporium michoacanense from soil. New Zealand , Acrodontium metrosideri on Metrosideros excelsa, Polynema podocarpi on Podocarpus totara, Pseudoarthrographis phlogis (incl. Pseudoarthrographis gen. nov.) on Phlox subulata. Nigeria, Coprinopsis afrocinerea on soil. Pakistan, Russula mansehraensis on soil under Pinus roxburghii. Russia, Baorangia alexandri on soil in deciduous forests with Quercus mongolica. South Africa, Didymocyrtis brachylaenae on Brachylaena discolor. Spain, Alfaria dactylis from fruit of Phoenix dactylifera, Dothiora infuscans from a blackened wall, Exophiala nidicola from the nest of an unidentified bird, Matsushimaea monilioides from soil, Terfezia morenoi on soil. United Arab Emirates, Tirmania honrubiae on soil. USA, Arxotrichum wyomingense (incl. Arxotrichum gen. nov.) from soil, Hongkongmyces snookiorum from submerged detritus from a fresh water fen, Leratiomyces tesquorum from soil, Talaromyces tabacinus on leaves of Nicotiana tabacum. Vietnam, Afroboletus vietnamensis on soil in an evergreen tropical forest, Colletotrichum condaoense from Ipomoea pes-caprae. Morphological and culture characteristics along with DNA barcodes are provided